
CLAIMS

1. A compound of formula (I):



(I)


wherein

Q is N or CR^a, where R^a is selected from hydrogen, OH, alkyl, alkoxy;


X, Y and Z are each selected independently from N or CR^b, where R^b is selected from hydrogen, alkoxy, alkyl, halo alkyl, halogen;


V is selected from the group consisting of: CO, SO and SO_2;


R^1 is selected from the group consisting of: alkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxy, cycloalkyl, a 4-7 membered saturated or unsaturated heterocyclic ring having heteroatoms selected from N, S and O optionally substituted with hydroxyl, nitrile, oxo, amino, aminoalkyl and/or dioxo, sulfonyl, sulfoxide, sulfoximine, alkyl sulfonyl, alkyl sulfoxide, cycloalkyl sulfonyl, cycloalkyl sulfoxide, sulfamoyl, alkyl sulfamoyl, cycloalkyl sulfamoyl; or one of the following structures:



, or any one of the following structures:







where each of the aforementioned hydrocarbon groups may be further substituted by one or more residues independently selected from halogen, hydroxyl, nitrile or C1-4-alkoxy groups;

R^2 is selected from the group consisting of: hydrogen, C1-3 alkyl, C1-3 alkoxyl, or C1-3 haloalkyl; or


R^1 and R^2 together form a 4-7 membered ring; particularly a 5-6 membered heterocyclic ring having a further heteroatom selected from N, or O, which is optionally substituted with oxo, amino, aminoalkyl, sulfoxide, sulfoxide imine, sulfonyl, alkyl sulfoxide, sulfoximine, alkyl sulfonyl, cycloalkyl sulfoxide, cycloalkyl sulfonyl, sulfamoyl, alkyl sulfamoyl, cycloalkyl sulfamoyl;

R^3 is selected from the group consisting of: hydrogen, C1-3 alkyl, C1-3 alkoxyl, or C1-3 haloalkyl; or

R^4 and R^5 are each independently selected from the group consisting of: hydrogen, C1-3 alkyl, pyridinyl, phenyl, pyrazidinyl or pyrimidinyl, optionally wherein the pyridinyl, phenyl, pyrazidinyl or pyrimidinyl is fused with a pyrrolyl, phenyl, pyrimidinyl, pyrazidinyl, imidazolyl, triazolyl, pyrazolyl, pyridinyl, quinolinyl, isoquinolinyl, quinazolinyl, which may be optionally substituted with C1-3 alkyl, C1-3 alkoxy, cyano, amine, difluoromethyl or halogen; or

R^4 and R^5 together with the Q to which they attach form a non-aromatic heterocyclic 4-8 membered ring containing at least one heteroatom, particularly nitrogen, and optionally an additional heteroatom such as nitrogen or oxygen; and wherein the ring is fused with phenyl, pyridinyl, pyrazidinyl, pyrimidinyl which may be optionally substituted with halogen, nitrile, methyl, methoxy, difluoromethyl, aminyl, or trifluoromethyl, pyrazidinyl or pyrimidinyl, wherein the phenyl, pyridinyl, pyrazidinyl or pyrimidinyl is optionally fused with a further heterocyclic 5- or 6-membered ring, which is optionally substituted with 1 to 3 groups selected from the group consisting of: C1-3 alkyl, C1-3 alkoxyl, C1-3 haloalkyl, pyrrolyl, imidazolyl, triazolyl, nitro, cyano, hydroxyl or halogen; or

R^4 and R^5 together with the Q to which they attach form one of the following structures:



,

M, R and A are selected independently from the group consisting of: N, S or C, preferably M and R are selected independently from the group consisting of: N, S or C and A is C;

U is selected from the group consisting of: N, or CR^c, wherein R^c is selected from hydrogen, halogen or alkyl;


R^6 and $R^{6'}$ are independently selected from the group consisting of: hydrogen, halogen C1-3 alkyl,C1-3 alkoxyl, C1-3 alkyl alkoxy, hydroxyl, alkyl hydroxyl, amino alkyl, C1-3 alkyl amino alkyl ,tertiary aminyl, cyclic aminyl , spirocyclic aminyl, C1-2 alkyl-4-6 saturated heterocyclic aminyl, C0-2 alkyl oxetane, C0-2 alkyl oxolane, C0-2 alkyl azetidinyl or C0-2 alkyl pyrrolidinyl, C1-3 carboxyl, C1-3 haloalkyl, methylacetyl (OAc) or ethanoate;

alternatively, $R^{6'}$ and R^6 together form a C3-5 membered saturated ring or C4-5 membered saturated heterocycle ring containing oxygen;

R^7 is selected from the group consisting of: C1-3 alkyl, C1-3 alkoxyl, C1-3 haloalkyl, nitro, cyano, SMe, SOMe, SO_2Me, pyrrolyl, imidazolyl, triazolyl, or halogen,; and

R^8 and R^9 are each independently selected from the group consisting of: hydrogen, C1-3 alkyl, C1-3 alkoxyl, hydroxyl, C1-3 hydroxyalkyl or halogen.

2. A pharmaceutical composition comprising a compound of formula (I):



(I)

or a pharmaceutically acceptable salt, solvate, prodrug, or pharmaceutically active metabolite thereof, or combinations thereof, and one or more pharmaceutically acceptable carrier,





wherein


Q is N or CR^a, where R^a is selected from hydrogen, OH, alkyl, alkoxy;


X, Y and Z are each selected independently from N or CR^b, where R^b is selected from hydrogen, alkoxy, alkyl, halo alkyl, halogen;


V is selected from the group consisting of: CO, SO and SO_2;

R^1 is selected from the group consisting of: alkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxy, cycloalkyl, a 4-7 membered saturated or unsaturated heterocyclic ring having heteroatoms selected from N, S and O optionally substituted with hydroxyl, nitrile, oxo, amino, aminoalkyl and/or dioxo, sulfonyl, sulfoxide, sulfoximine, alkyl sulfonyl, alkyl sulfoxide, cycloalkyl sulfonyl, cycloalkyl sulfoxide, sulfamoyl, alkyl sulfamoyl, cycloalkyl sulfamoyl; or one of the following structures:


,

,

, or

, or any one of the following structures:







where each of the aforementioned hydrocarbon groups may be further substituted by one or more residues independently selected from halogen, hydroxyl, nitrile or C1-4-alkoxy groups;

R^2 is selected from the group consisting of: hydrogen, C1-3 alkyl, C1-3 alkoxyl, or C1-3 haloalkyl; or


R^1 and R^2 together form a 4-7 membered ring; particularly a 5-6 membered heterocyclic ring having a further heteroatom selected from N, or O, which is optionally substituted with oxo, amino, aminoalkyl, sulfoxide, sulfoxide imine, sulfonyl, alkyl sulfoxide, sulfoximine, alkyl sulfonyl, cycloalkyl sulfoxide, cycloalkyl sulfonyl, sulfamoyl, alkyl sulfamoyl, cycloalkyl sulfamoyl;


R^3 is selected from the group consisting of: hydrogen, C1-3 alkyl, C1-3 alkoxyl, or C1-3 haloalkyl; or

R^4 and R^5 are each independently selected from the group consisting of: hydrogen, C1-3 alkyl, pyridinyl, phenyl, pyrazidinyl or pyrimidinyl, optionally wherein the pyridinyl, phenyl, pyrazidinyl or pyrimidinyl is fused with a pyrrolyl, phenyl, pyrimidinyl, pyrazidinyl, imidazolyl, triazolyl, pyrazolyl, pyridinyl, quinolinyl, isoquinolinyl, quinazolinyl, which may be optionally substituted with C1-3 alkyl, C1-3 alkoxy, cyano, amine, difluoromethyl or halogen; or

R^4 and R^5 together with the Q to which they attach form a non-aromatic heterocyclic 4-8 membered ring containing at least one heteroatom, particularly nitrogen, and optionally an additional heteroatom such as nitrogen or oxygen; and wherein the ring is fused with phenyl, pyridinyl, pyrazidinyl, pyrimidinyl which may be optionally substituted with halogen, nitrile, methyl, methoxy, difluoromethyl, aminyl, or trifluoromethyl, pyrazidinyl or pyrimidinyl, wherein the phenyl, pyridinyl, pyrazidinyl or pyrimidinyl is optionally fused with a further heterocyclic 5- or 6-membered, which is optionally substituted with 1 to 3 groups selected from the group consisting of: C1-3 alkyl, C1-3 alkoxyl, C1-3 haloalkyl, pyrrolyl, imidazolyl, triazolyl, nitro, cyano, hydroxyl or halogen; or

R^4 and R^5 together with the Q to which they attach form one of the following structures:



, or


,

M, R and A are selected independently from the group consisting of: N, S or C, preferably M and R are selected independently from the group consisting of: N, S or C and A is C;

U is selected from the group consisting of: N, or CR^c, wherein R^c is selected from hydrogen, halogen or alkyl;

R^6 and $R^{6'}$ are independently selected from the group consisting of: hydrogen, halogen C1-3 alkyl, C1-3 alkoxyl, C1-3 alkyl alkoxy, hydroxyl, alkyl hydroxyl, amino alkyl, C1-3 alkyl amino alkyl, tertiary aminyl, cyclic aminyl , spirocyclic aminyl, C1-2 alkyl-4-6 saturated heterocyclic aminyl, C0-2 alkyl oxetane, C0-2 alkyl oxolane, C0-2 alkyl azetidinyl or C0-2 alkyl pyrrolidinyl, C1-3 carboxyl, C1-3 haloalkyl, methylacetyl (Oac) or ethanoate;

alternatively, $R^{6'}$ and R^6 together form a C3-5 membered saturated ring or C4-5 membered saturated heterocycle ring containing oxygen;

R^7 is selected from the group consisting of: C1-3 alkyl, C1-3 alkoxyl, C1-3 haloalkyl, nitro, cyano, Sme, SOMe, SO_2Me, pyrrolyl, imidazolyl, triazolyl, or halogen; and

R^8 and R^9 are each independently selected from the group consisting of: hydrogen, C1-3 alkyl, C1-3 alkoxyl, hydroxyl, C1-3 hydroxyalkyl or halogen.

3. The compound of Claim 1 or the pharmaceutical composition of Claim 2, wherein:


(i) Q is N and V is CO; or Q is CR^a, wherein R^a is hydrogen, hydroxyl or methoxy and V is CO; and/or


(ii) X, Y and Z are CH; or one of X and Y is CF, the other one of X and Y is CH and Z is CH; and/or

(iii) R^2 is methyl; and/or

(iv) R^3 is CF_2CH_3, CF_2H or CF_3.

4. The compound of Claim 1 or Claim 3, or the pharmaceutical composition of Claim 2 or Claim 3, wherein R^5 is hydrogen or methyl, and R^4 is one of the following structures:



, or


;

wherein

M, R and A are selected independently from the group consisting of: N, S or C;

U is selected from the group consisting of: N, S or CR^c, wherein R^c is selected from hydrogen, halogen or alkyl;

R^7 is selected from the group consisting of: C1-3 alkyl, C1-3 alkoxyl, C1-3 haloalkyl, nitro, cyano, SMe, SOMe, SO_2Me, pyrrolyl, imidazolyl, triazolyl, or halogen;

R^8 and R^9 where present are each independently selected from the group consisting of: hydrogen, C1-3 alkyl, C1-3 alkoxyl, hydroxyl, C1-3 hydroxyalkyl or halogen; and

R^{10} is selected from the group consisting of: hydrogen, C1-3 alkyl, C1-3 alkoxyl, C1-3 hydroxy alkyl, halogen, amide, C3-5 membered saturated ring or C4-5 membered saturated heterocycle ring, wherein said ring is optionally substituted with OMe or halogen.

5. The compound or pharmaceutical composition of Claim 4, wherein

(i) M and R are selected independently from the group consisting of: N or C; and A is selected independently from the group consisting of: N, S or C; preferably A is C; and/or

(ii) at least two of X, Y and Z are C; and/or

(iii) R^7 is chlorine, fluorine or methoxy; and/or


(iv) U and M are N, and R and A are C; and/or

(v) R^7 is chlorine, U and M are N, and R and A are C; or R^7 is methoxy, U is N and R and M are C; and/or


(vi) R8 and R9 are each independently selected from hydrogen, methyl, hydroxyl, methoxy or chlorine; or R8 and R9 are hydrogen






(vii) R^{10} is selected from the group consisting of: $CHOMeCH_3$, $CHOHCH_3$, $COCH_3$, CH_2OCH_3, $CH_2Ocyclopropyl$, $CHNH_2CH_3$, $CHNHMeCH_3$, $CHNMe_2CH_3$, CO-aziridine amide, cyclopropyl, tetrahydrofuran or oxetane, wherein said cyclopropyl, tetrahydrofuran or oxetane is optionally substituted with OMe or fluorine.

6. The compound or pharmaceutical composition of Claim 4 or Claim 5, wherein R^1 is selected from the group consisting of the following structures:



7. The compound or pharmaceutical composition of any of Claims 4 to 6, wherein R^4 is selected from the group consisting of:



, , , , 

or .

8. The compound of Claim 1 or Claim 3 or pharmaceutical composition of Claim 2 or Claim 3, wherein:

U is N and/or R is N; or

U is selected from N or CR^c or

U is N, and/or one of R and M is N and the other is C.

9. The compound of any of Claims 1, 3 or 8 or pharmaceutical composition of any of Claims 2, 3 or 8, wherein:

R^6 and $R^{6'}$ are both methyl; or

R^6 is methyl or CH_2OMe and $R^{6'}$ is H; or

R^6 and $R^{6'}$ are both H; or

R^6 and/or $R^{6'}$ are independently selected from the group consisting of: hydrogen, fluorine, methyl, ethyl, methoxy, ethoxy, hydroxyl, CH2OH, CH2OMe, CH2NHMe and CH2N(Me)2; preferably wherein one of R^6 and $R^{6'}$ is installed in the benzylic position.

10. The compound of any of Claims 1, 3, 8 or 9, or pharmaceutical composition of any of Claims 2, 3, 8 or 9, wherein:

R^7 is fluorine, chlorine, methyl or methoxy; and/or

R^8 and R^9 are each independently selected from hydrogen, hydroxyl, fluorine or chlorine; and/or

R^8 is chlorine or hydrogen, and R^9 is H.

11. The compound of any of Claims 1, 3, or 8 to 10, or pharmaceutical composition of any of Claims 2, 3, or 8 to 10, wherein:









R and M are each independently selected from N or C; and/or

A is selected from S or C; and/or

A is S, and M and R are C.











12. The compound of any of Claims 1, 3, or 8 to 11, or pharmaceutical composition of any of Claims 2, 3, or 8 to 11, wherein R^3 is selected from the group consisting of: haloalkyl, trihaloalkyl or trifluoromethyl.

13. The compound of any of Claims 1, 3, or 8 to 12, or pharmaceutical composition of any of Claims 2, 3, or 8 to 12, wherein R^4 and R^5 together form any one of the following tricyclic structures:













,

,

,

,

,

,

,or

.

14. The compound of any of Claims 1, 3, or 8 to 13, or pharmaceutical composition of any of Claims 2, 3, or 8 to 13, wherein R^6 and/or $R^{6'}$ are independently selected from the group consisting of hydrogen, methyl, fluorine, methoxy, CH_2OMe, CH_2NHMe, $CH_2NH(Me)_2$, CH_2-azetidinyl, CH_2-pyrrolidinyl or CH_2-morpholinyl or trifluoromethyl; or R^6 and $R^{6'}$ together form cyclopropyl, oxetane or tetrahydrofuran, preferably wherein R^6 and/or $R^{6'}$ are selected from H or Me and optionally n is 2.

15. The compound of any of Claims 1 or 3 to 14, wherein R^4 and R^5 together form any one of the following tricyclic structures:



,

,

,

,

,

,

,

,

, or


or the pharmaceutical composition of any of Claims 2 to 14, wherein R^4 and R^5 together form any one of the following tricyclic structures:


,

,

,

,

,

,

,

,

,

, or

.

16. The compound of any of Claims 1 or 3 to 15, or pharmaceutical composition of any of Claims 2 to 15, wherein R^6 is selected from the group consisting of Me, Ome, CH_2Ome and OH and $R^{6'}$ is hydrogen.

17. The compound of any of Claims 1 or 3 to 16, or pharmaceutical composition of any of Claims 2 to 16, wherein R^1 is selected from CH_2OH, CH_2CN, or ethyl; or from the group consisting of the following structures:



;

optionally further substituted with alkyl, alkenyl, alkynyl, alkoxy.

18. A compound or pharmaceutical composition comprising a compound, wherein the compound is selected from:

(i) the group of compounds shown in Table 1;

(ii) the group of compounds of Table 1 having an IC50 against Malt-1 ≤ 250 nM;

(iii) the group of compounds of Table 1 having an IC50 against Malt-1 ≤ 200 nM;

(iv) the group of compounds of Table 1 having an IC50 against Malt-1 ≤ 150 nM;

(v) the group of compounds of Table 1 having an IC50 against Malt-1 ≤ 100 nM;

(vi) the group of compounds of Table 1 having an IC50 against Malt-1 ≤ 50 nM; or

(vii) the group of compounds of Table 1 having an IC50 against Malt-1 ≤ 25 nM.

19. A compound or pharmaceutical composition comprising a compound, wherein the compound is selected from any one of the compounds of Examples 1 to 295, or a pharmaceutically acceptable salt, solvate, prodrug, or pharmaceutically active metabolite thereof, or combinations thereof, and one or more pharmaceutically acceptable carrier.

20. Use of the compound according to any of Claims 1 or 3 to 19, or the pharmaceutical composition according to any of Claims 2 to 19 for the manufacture of a medicament for use in the treatment of autoimmune disorders, inflammatory diseases, cancers and/or oncologic diseases, optionally wherein the disorders or diseases are selected from the group consisting of: rheumatoid arthritis, multiple sclerosis, psoriasis, Sjogren's syndrome and systemic lupus erythematosus or vasculitic conditions, cancers of hematopoietic origin or solid tumors, including chronic myelogenous leukemia, myeloid leukemia, non-Hodgkin lymphoma and other B cell lymphomas.

21. The compound according to any of Claims 1 or 3 to 19, the pharmaceutical composition according to any of Claims 2 to 19, use of the compound or use of the pharmaceutical composition according to Claim 20, wherein the compound is an inhibitor of MALT-1.

22. Use of the compound or use of the pharmaceutical composition according to Claim 20 or Claim 21, wherein the use is in a method comprising:

(i) administering the compound orally, topically, by inhalation, by intranasal administration, or systemically by intravenous, intraperitoneal, subcutaneous, or intramuscular injection, and/or

(ii) administering the compound according to Formula (I) in combination with one or more additional therapeutic agent.

23. Use of the compound or use of the pharmaceutical composition according to any of Claims 20 to 22, wherein the use is in a method comprising administering to a subject an effective amount of the compound of Formula (I), wherein the effective amount is between about 500 nM and about 10 μM in the blood of the subject.